Summary & Overview
HCPCS J2590: Oxytocin Injection, Up to 10 Units
HCPCS Level II code J2590 denotes an injectable dose of oxytocin, billed for up to 10 units. Oxytocin injections are commonly used in obstetric care for induction or augmentation of labor and for management of postpartum hemorrhage, making this code relevant across inpatient and outpatient maternity settings nationwide. Accurate coding for J2590 affects billing for medication administration and institutional drug reporting and supports appropriate tracking of obstetric drug utilization.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines how these major payers typically handle billing for injectable oxytocin, with attention to coverage scope and common billing practices.
Readers will find concise benchmarks and policy context relevant to J2590, including typical sites of service, common modifier usage (listed elsewhere in this document), and clinical scenarios where the code is applied. The summary also covers coding considerations for institutional claims and highlights areas where payers' administrative requirements commonly intersect with clinical documentation. Data not available in the input are clearly marked in corresponding sections.
Billing Code Overview
HCPCS Level II code J2590 represents an injection of oxytocin, billed for up to 10 units per administration. This service is typically used to induce or augment labor or to control postpartum bleeding, as appropriate to clinical practice.
Service Type: Drug administration (injectable medication)
Typical Site of Service: Inpatient hospital, outpatient hospital, labor and delivery unit, or ambulatory surgical center
Clinical & Coding Specifications
Clinical Context
A typical patient is a laboring pregnant person in active labor or postpartum with uterine atony where uterine contraction augmentation or hemorrhage control is required. Intrapartum use occurs when induction or augmentation of labor is indicated for conditions such as post-term pregnancy, premature rupture of membranes with need for induction, intrauterine fetal growth restriction with nonreassuring testing, or inadequate uterine contractions during labor. Postpartum use occurs immediately after delivery when uterine atony causes excessive bleeding and uterotonic therapy is required.
Common clinical workflow: the obstetrician, maternal-fetal medicine specialist, certified nurse-midwife, or labor and delivery nurse documents the indication (e.g., induction, augmentation, postpartum hemorrhage), obtains informed consent, prepares oxytocin per protocol, and administers J2590 intravenously via infusion pump (for augmentation/induction) or as an intravenous/IM bolus per institutional guideline for hemorrhage management. Vital signs, uterine tone, contraction pattern, fetal monitoring, and estimated blood loss are monitored. Additional uterotonics or interventions (bimanual massage, uterine massage, balloon tamponade, surgical management) may follow if bleeding persists. Medication administration is recorded in the medication administration record and the delivery/anesthesia records as applicable.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |